BR112015028499A2 - Peptídeo para induzir apoptose específica de mastócito e uso do mesmo - Google Patents
Peptídeo para induzir apoptose específica de mastócito e uso do mesmoInfo
- Publication number
- BR112015028499A2 BR112015028499A2 BR112015028499A BR112015028499A BR112015028499A2 BR 112015028499 A2 BR112015028499 A2 BR 112015028499A2 BR 112015028499 A BR112015028499 A BR 112015028499A BR 112015028499 A BR112015028499 A BR 112015028499A BR 112015028499 A2 BR112015028499 A2 BR 112015028499A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- present
- mast cell
- induce specific
- cell apoptosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
PEPTÍDEO PARA INDUZIR APOPTOSE ESPECÍFICA DE MASTÓCITO E USO DO MESMO. Trata-se de um peptídeo que, de acordo com a presente invenção, pode desempenhar uma função idêntica ou similar à função de CTLA-4 natural e tem um grau excelente de penetração na pele devido a um tamanho pequeno. O peptídeo, de acordo com a presente invenção, se liga de modo eficaz a um antígeno que apresenta proteínas de superfície celular (CD80 e CD86) para inibir atividade de células T e. desse modo, tem capacidade de inibir a expressão de citocinas inflamatórias (por exemplo, IL-2 e IFN-Y). Como resultado, uma composição que compreende o peptídeo de acordo com a presente invenção exibe efeitos excelente em termos de prevenção, tratamento, ou melhoramento de doenças imunes mediadas por Th1. Portanto, a atividade e a estabilidade superiores do peptídeo de acordo com a presente invenção podem ser úteis quando aplicadas a medicamentos, produtos parafarmacêuticos, e cosméticos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130053779A KR101510742B1 (ko) | 2013-05-13 | 2013-05-13 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
| PCT/KR2013/009601 WO2014185604A1 (ko) | 2013-05-13 | 2013-10-25 | 비만세포-특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015028499A2 true BR112015028499A2 (pt) | 2017-09-19 |
Family
ID=51898560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015028499A BR112015028499A2 (pt) | 2013-05-13 | 2013-10-25 | Peptídeo para induzir apoptose específica de mastócito e uso do mesmo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637519B2 (pt) |
| EP (1) | EP2998313B1 (pt) |
| JP (1) | JP6117993B2 (pt) |
| KR (1) | KR101510742B1 (pt) |
| CN (1) | CN105308064B (pt) |
| BR (1) | BR112015028499A2 (pt) |
| ES (1) | ES2704859T3 (pt) |
| WO (1) | WO2014185604A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| AU2017299513A1 (en) * | 2016-07-19 | 2019-02-28 | Arete Discoveries, Inc. | Biomarkers for detection and treatment of mast cell activity-associated disorders |
| KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR101943083B1 (ko) * | 2017-03-30 | 2019-01-29 | (주)케어젠 | 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도 |
| CN107353333A (zh) * | 2017-06-29 | 2017-11-17 | 西安交通大学医学院第附属医院 | 一种骨保护性分子Semaphorine3A及其制药应用 |
| KR102380735B1 (ko) * | 2020-07-16 | 2022-04-01 | (주)케어젠 | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 |
| WO2022015069A1 (ko) * | 2020-07-16 | 2022-01-20 | (주)케어젠 | 제2형 중증급성호흡기증후군 코로나바이러스에 중화 활성을 갖는 펩타이드 |
| KR102522579B1 (ko) * | 2021-02-08 | 2023-04-18 | 중앙대학교 산학협력단 | 히스타민 특이 결합 펩타이드 및 이를 이용한 히스타민 검출용 조성물 |
| KR20240043270A (ko) | 2022-09-27 | 2024-04-03 | 김건웅 | 인공지능을 활용한 기업과 인플루언서 상호 매칭시스템 및 매칭방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1429801A1 (en) * | 2001-09-26 | 2004-06-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Neuropilin as a novel therapeutic target for modulation of immune reponses |
| US7781413B2 (en) * | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| EP2210092B1 (en) | 2007-10-19 | 2014-06-11 | Rappaport Family Institute for Research in the Medical Sciences | Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof |
| JP2010154842A (ja) * | 2008-12-03 | 2010-07-15 | Koji Kawakami | Ｅｇｆｒを標的にした新規抗がんキメラペプチド |
| KR20100115910A (ko) * | 2009-04-21 | 2010-10-29 | 광주과학기술원 | 심부전, 섬유증 또는 염증 치료제의 스크리닝 방법 및 이를 포함하는 조성물 |
| EP3275898B1 (en) * | 2009-11-05 | 2024-06-05 | Osaka University | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent |
-
2013
- 2013-05-13 KR KR20130053779A patent/KR101510742B1/ko active IP Right Grant
- 2013-10-25 US US14/888,017 patent/US9637519B2/en active Active
- 2013-10-25 CN CN201380076560.9A patent/CN105308064B/zh active Active
- 2013-10-25 BR BR112015028499A patent/BR112015028499A2/pt not_active Application Discontinuation
- 2013-10-25 WO PCT/KR2013/009601 patent/WO2014185604A1/ko active Application Filing
- 2013-10-25 EP EP13884437.8A patent/EP2998313B1/en active Active
- 2013-10-25 JP JP2016513853A patent/JP6117993B2/ja active Active
- 2013-10-25 ES ES13884437T patent/ES2704859T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160075739A1 (en) | 2016-03-17 |
| CN105308064A (zh) | 2016-02-03 |
| WO2014185604A1 (ko) | 2014-11-20 |
| EP2998313A1 (en) | 2016-03-23 |
| KR20140134083A (ko) | 2014-11-21 |
| JP6117993B2 (ja) | 2017-04-19 |
| EP2998313A4 (en) | 2016-12-21 |
| CN105308064B (zh) | 2019-01-11 |
| KR101510742B1 (ko) | 2015-04-10 |
| US9637519B2 (en) | 2017-05-02 |
| EP2998313B1 (en) | 2018-10-10 |
| ES2704859T3 (es) | 2019-03-20 |
| JP2016520587A (ja) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015028499A2 (pt) | Peptídeo para induzir apoptose específica de mastócito e uso do mesmo | |
| BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| BR112017022845A2 (pt) | neoepítopos de câncer | |
| AR105600A1 (es) | Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
| BR112020009655A8 (pt) | Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica | |
| UY36538A (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
| BR112017011780A2 (pt) | inibidor de bromodomínio como composto auxiliar na imunoterapia para câncer | |
| CR20150390A (es) | Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2) | |
| CL2018000963A1 (es) | Cosmética que tiene bacterias probióticas | |
| BR112016013832A2 (pt) | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico | |
| BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
| BR112018070852A2 (pt) | composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112015008143A2 (pt) | complexos, polipeptídeo e/ou polinucleotídeo isolado e purificado, composições, métodos para preparar, produzir ou obter complexos, para expandir e/ou desenvolver populações de células t autorreativas antipatogênicas e/ou para tratar esclerose múltipla ou distúrbio relacionado em sujeito com essa necessidade, kit e uso de complexos, de polipeptídeo e/ou de polinucleotídeo isolados e purificados e/ou de composições |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |